The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | Huge potential for CAR-T therapy in myeloma
Talking at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France, Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, expresses his excitement about the progression of CAR-T cell therapy in the field of multiple myeloma (MM). Dr Yee highlights that there should be a focus on treatment earlier in the patient’s journey because it would be more effective and many patients that would develop further complications and would not be able to receive these therapies would also benefit. Dr Yee also highlights the work in the KarMMa-2 trial (NCT03601078), which is studying the safety and efficacy of idecabtagene vicleucel (bb2121) in patients with relapsed and refractory MM.
